Platelet factor 4-containing immune complexes induce platelet activation followed by calpain-dependent platelet death.
Autoimmunity
Mechanisms of disease
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
2019
2019
Historique:
received:
24
04
2019
revised:
29
05
2019
accepted:
05
06
2019
entrez:
3
7
2019
pubmed:
3
7
2019
medline:
3
7
2019
Statut:
epublish
Résumé
Heparin-induced thrombocytopenia (HIT) is a complication of heparin therapy sometimes associated with thrombosis. The hallmark of HIT is antibodies to the heparin/platelet factor 4 (PF4) complex that cause thrombocytopenia and thrombosis through platelet activation. Despite the clinical importance, the molecular mechanisms and late consequences of immune platelet activation are not fully understood. Here, we studied immediate and delayed effects of the complexes formed by human PF4 and HIT-like monoclonal mouse anti-human-PF4/heparin IgG antibodies (named KKO) on isolated human platelets in vitro. Direct platelet-activating effect of the KKO/PF4 complexes was corroborated by the overexpression of phosphatidylserine (PS) and P-selectin on the platelet surface. The immune platelet activation was accompanied by a decrease of the mitochondrial transmembrane potential (ΔΨm), concurrent with a significant gradual reduction of the ATP content in platelets, indicating disruption of energy metabolism. A combination of PS expression and mitochondrial depolarization induced by the PF4-containing immune complexes observed in a substantial fraction of platelets was considered as a sign of ongoing platelet death, as opposed to a subpopulation of activated live platelets with PS on the plasma membrane but normal ΔΨm. Both activated and dying platelets treated with KKO/PF4 formed procoagulant extracellular microvesicles bearing PS on their surface. Scanning and transmission electron microscopy revealed dramatic morphological changes of KKO/PF4-treated platelets, including their fragmentation, another indicator of cell death. Most of the effects of KKO/PF4 were prevented by an anti-FcγRII monoclonal antibody IV.3. The adverse functional and structural changes in platelets induced by the KKO/PF4 complexes were associated with strong time-dependent activation of calpain, but only trace cleavage of caspase 3. The results indicate that the pathogenic PF4-containing HIT-like immune complexes induce direct prothrombotic platelet activation via FcγRIIA receptors followed by non-apoptotic calpain-dependent death of platelets, which can be an important mechanism of thrombocytopenia during HIT development.
Identifiants
pubmed: 31263574
doi: 10.1038/s41420-019-0188-0
pii: 188
pmc: PMC6591288
doi:
Types de publication
Journal Article
Langues
eng
Pagination
106Déclaration de conflit d'intérêts
Conflict of interestThe authors declare that they have no conflict of interest.
Références
Blood. 2000 Jul 1;96(1):188-94
pubmed: 10891450
Blood. 2000 Aug 1;96(3):846-51
pubmed: 10910895
Blood. 2000 Dec 15;96(13):4254-60
pubmed: 11110699
Blood. 2001 Oct 15;98(8):2442-7
pubmed: 11588041
J Lab Clin Med. 2001 Dec;138(6):393-402
pubmed: 11753286
Int Immunol. 2002 Feb;14(2):121-9
pubmed: 11809731
Blood. 2003 Apr 15;101(8):2955-9
pubmed: 12480713
Transfus Apher Sci. 2003 Jun;28(3):285-95
pubmed: 12725956
Transfusion. 2003 Jul;43(7):857-66
pubmed: 12823744
Arch Intern Med. 2003 Aug 11-25;163(15):1849-56
pubmed: 12912723
Semin Thromb Hemost. 2004 Feb;30 Suppl 1:57-67
pubmed: 15085467
Biochem Biophys Res Commun. 2004 Jul 23;320(2):303-10
pubmed: 15219827
Blood. 2005 Dec 1;106(12):3791-6
pubmed: 16109780
Ann Clin Biochem. 2005 Nov;42(Pt 6):415-31
pubmed: 16259792
Blood. 2006 Mar 15;107(6):2346-53
pubmed: 16304054
FEBS J. 2006 Aug;273(15):3437-43
pubmed: 16884489
J Thromb Haemost. 2006 Dec;4(12):2656-63
pubmed: 16961585
Cell. 2007 Mar 23;128(6):1173-86
pubmed: 17382885
Blood. 2008 Jan 1;111(1):165-74
pubmed: 17848620
Blood. 2009 May 14;113(20):4963-9
pubmed: 19144981
J Thromb Haemost. 2009 Jul;7 Suppl 1:249-52
pubmed: 19630810
Arch Biochem Biophys. 2010 Mar 1;495(1):1-7
pubmed: 20035707
Blood. 2010 Dec 2;116(23):5021-31
pubmed: 20724543
J Thromb Haemost. 2011 Apr;9(4):885-7
pubmed: 21320287
Int J Mol Sci. 2011;12(4):2125-37
pubmed: 21731431
Methods Mol Biol. 2012;788:59-71
pubmed: 22130700
J Thromb Thrombolysis. 2012 May;33(4):397-411
pubmed: 22383127
Vascul Pharmacol. 2012 May-Jun;56(5-6):210-5
pubmed: 22386643
Br J Haematol. 2012 Dec;159(5):565-71
pubmed: 23025479
J Biol Chem. 2013 Nov 15;288(46):33060-70
pubmed: 24097975
Hematology Am Soc Hematol Educ Program. 2013;2013:668-74
pubmed: 24319250
Blood. 2015 Apr 9;125(15):2397-404
pubmed: 25680756
Blood. 2016 Jan 28;127(4):464-72
pubmed: 26518435
Autoimmun Rev. 2016 Jul;15(7):752-5
pubmed: 26970483
Thromb Haemost. 2016 Oct 28;116(5):799-805
pubmed: 27358188
Thromb Haemost. 2016 Oct 28;116(5):792-798
pubmed: 27465274
PLoS One. 2016 Aug 05;11(8):e0160563
pubmed: 27494140
J Mol Recognit. 2017 Mar;30(3):
pubmed: 27790761
Thromb Res. 1989 Jul 15;55(2):291-5
pubmed: 2781529
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):262-268
pubmed: 27913490
Cytometry B Clin Cytom. 2018 Mar;94(2):334-341
pubmed: 28052584
Platelets. 2017 May;28(3):263-271
pubmed: 28102751
Blood. 2017 May 25;129(21):2864-2872
pubmed: 28416511
Nat Commun. 2017 May 22;8:14945
pubmed: 28530237
J Thromb Haemost. 2017 Nov;15(11):2099-2114
pubmed: 28846826
Haematologica. 2019 Feb 21;:null
pubmed: 30792211
Blood. 1988 Sep;72(3):925-30
pubmed: 3416077
Biochem J. 1995 Oct 15;311 ( Pt 2):471-8
pubmed: 7487883
Blood. 1994 Dec 1;84(11):3691-9
pubmed: 7949124
Eur J Biochem. 1996 Aug 1;239(3):647-54
pubmed: 8774708
Br J Haematol. 1997 Dec;99(4):824-31
pubmed: 9432028